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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that targets motor
neurons, leading to paralysis and death within a few years of disease onset. While several
genes have been linked to the inheritable, or familial, form of ALS, much less is known
about the cause(s) of sporadic ALS, which accounts for ∼90% of ALS cases. Due to the
clinical similarities between familial and sporadic ALS, it is plausible that both forms of
the disease converge on a common pathway and, therefore, involve common factors.
Recent evidence suggests the Cu,Zn-superoxide dismutase (SOD1) protein to be one
such factor that is common to both sporadic and familial ALS. In 1993, mutations were
uncovered in SOD1 that represent the first known genetic cause of familial ALS. While
the exact mechanism of mutant-SOD1 toxicity is still not known today, most evidence
points to a gain of toxic function that stems, at least in part, from the propensity of
this protein to misfold. In the wild-type SOD1 protein, non-genetic perturbations such as
metal depletion, disruption of the quaternary structure, and oxidation, can also induce
SOD1 to misfold. In fact, these aforementioned post-translational modifications cause
wild-type SOD1 to adopt a “toxic conformation” that is similar to familial ALS-linked
SOD1 variants. These observations, together with the detection of misfolded wild-type
SOD1 within human post-mortem sporadic ALS samples, have been used to support the
controversial hypothesis that misfolded forms of wild-type SOD1 contribute to sporadic
ALS pathogenesis. In this review, we present data from the literature that both support
and contradict this hypothesis. We also discuss SOD1 as a potential therapeutic target for
both familial and sporadic ALS.
Keywords: amyotrophic lateral sclerosis (ALS), sporadic amyotrophic lateral sclerosis, SOD1, protein misfolding,
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common motor
neuron disease and is clinically characterized by the degeneration
of motor neurons in the brain and spinal cord, culminating in
paralysis and death within 2–5 years. The only available treatment
is riluzole, which in the best cases extends survival by only a few
months (Glicksman, 2011). In 1993, mutations in the SOD1 gene
encoding Cu,Zn superoxide dismutase-1 were reported as the first
genetic link to familial, or inherited, forms of ALS (FALS) (Rosen
et al., 1993). Because of the high incidence of SOD1 mutations,
which account for 20–25% of FALS cases, SOD1 has been one of
the most intensely studied genes in the ALS field and continues to
be a primary therapeutic target (Bosco and Landers, 2010).
Much of what we understand about the pathomechanisms of
ALS is based on in vivo studies with transgenic rodent models
expressing FALS-linked SOD1 variants. These FALS-SOD1 ani-
mal models recapitulate many key features of the human disease,
including motor neuron degeneration, paralysis and shortened
life-span (Turner and Talbot, 2008). Moreover, FALS-SOD1 ani-
mal models reveal the complex nature of this disease, which
involves oxidative stress, a loss of proteostasis (i.e., protein aggre-
gation with defective protein clearance), mitochondrial dysfunc-
tion, impaired axonal transport, and glutamate excitotoxicity
(Rothstein, 2009). While motor neurons are the primary target
in ALS, ALS may actually represent a non-cell autonomous disor-
der for which glia play an active role (Ilieva et al., 2009). Despite
decades of research on FALS-SOD1 in vitro and in vivo, the exact
mechanism of SOD1 in ALS pathogenesis remains unknown
(Pasinelli and Brown, 2006; Ling et al., 2013). However, as will
be discussed throughout this review, a substantial body of litera-
ture points to a gain of toxic function for FALS-SOD1 that stems,
at least in part, from SOD1 misfolding.
In contrast to FALS, much less is known about the etiology
of sporadic ALS (SALS), which accounts for 90% of ALS cases.
Pathological aggregates composed of the TAR DNA-binding pro-
tein 43 (TDP-43) are detected in CNS tissues for a majority of
SALS cases (Neumann et al., 2006), providing strong evidence
for an association of misfolded TDP-43 with ALS pathogene-
sis (Xu, 2012). Mutations in TDP-43 have also been linked to
SALS and FALS (Sreedharan et al., 2008), further establishing
a role for this protein in disease. Another RNA-binding protein
called fused in sarcoma/translocated in liposarcoma (FUS/TLS)
has also been linked to FALS and SALS (Kwiatkowski et al.,
2009; Vance et al., 2009). Although the association of FUS/TLS
with pathological aggregates in SALS has been reported (Deng
et al., 2010), this association is not as common as for TDP-43.
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The inheritable nature of FALS facilitates the identification of
causal genes, because many FALS-linked genes, such as SOD1,
TDP-43 and FUS/TLS, are autosomal dominant and segregate
according to Mendelian genetics within an ALS family. In an
effort to identify genetic susceptibility factors associated with
SALS, several genome-wide association studies (GWAS) have
been performed. However, by and large these studies have failed
to generate confirmed SALS-susceptibility genes (Bosco and
Landers, 2010). More recently, repeat expansions within the
genome that are associated with different forms of ALS have been
identified. Hexanucleotide repeat expansions in the C9ORF72
gene were linked to familial frontotemporal lobar degeneration
(FTLD)/ALS, FALS as well as to SALS (Dejesus-Hernandez et al.,
2011; Renton et al., 2011), making this gene the most common
factor in all of ALS. Moreover, repeat expansions in ataxin-2
(ATXN2) represent a susceptibility factor in SALS (Elden et al.,
2010). Despite these advances in the genetics of SALS, the eti-
ology remains unknown for a majority of SALS cases, likely a
reflection of the complex nature of SALS. In fact, SALS may arise
from genetic as well as environmental and behavioral factors.
Smoking, diet, excessive exercise, injury and exposure to environ-
mental toxins have all been implicated in SALS (D’Amico et al.,
2013), although none have been shown to unequivocally cause
disease. Although FALS is inheritable and SALS is not, the fact
that FALS and SALS are clinically indistinguishable raises the pos-
sibility that they do in fact emerge from a common source and/or
involve similar toxicity factors.
Recent evidence supports SOD1 as a toxic factor that is com-
mon to a subset of both FALS and SALS. This evidence is largely
based on the observation that aberrant conformations of WT
SOD1, induced by oxidation, demetallation and other altered
post-translational modifications, cause WT SOD1 to acquire the
same toxic functions that are observed for FALS-associated SOD1
variants (Ezzi et al., 2007; Bosco et al., 2010; Guareschi et al.,
2012). Moreover, by employing conformation specific antibod-
ies that are selective for SOD1 only when it is mutated or has
altered post-translational modifications, misfolded “mutant-like”
WT SOD1 has been detected in human post-mortem tissues from
SALS individuals (Bosco et al., 2010; Forsberg et al., 2010, 2011;
Pokrishevsky et al., 2012), suggesting that such species are in
fact pathogenic. The concept that critical proteins can become
pathogenic via both germline mutations and non-Mendelian
post-translational modifications is not novel, but rather has
strong precedence in neurodegeneration with examples including
the α-synuclein (Beyer and Ariza, 2013), tau (Mandelkow et al.,
1996) and TDP-43 proteins (Arai et al., 2010). The concept that
WT SOD1 could play a role in SALS is controversial, since not all
conformation specific antibodies employed to date have detected
aberrant WT SOD1 species in SALS (Furukawa, 2012; Ling et al.,
2013). However, such a role should be strongly considered and
fully explored as it has important therapeutic implications for
treating both familial and sporadic forms of ALS.
NORMAL PROPERTIES AND CELLULAR FUNCTIONS OF SOD1
Long before SOD1 was identified as a causative factor in FALS
(Rosen et al., 1993), the anti-oxidizing and catalytic properties
of native SOD1 were being investigated (McCord and Fridovich,
1969). While the role of SOD1 as an anti-oxidizing enzyme
is well known and accepted, the role of SOD1 as a signaling
molecule has been relatively underappreciated. Herein we discuss
what is known regarding the normal functions of SOD1 in the
context of both anti-oxidation and signaling. The normal phys-
iological properties of SOD1 are discussed in order to establish
a foundation for the following sections that describe how both
FALS-linkedmutations and post-translational modifications alter
the structure and function of the protein.
SOD1: LOCATION, ACTIVITY, AND STRUCTURE
Copper,zinc- superoxide dismutase-1 (SOD1) is a member of
the human SOD family of proteins, which also includes SOD2
and SOD3. While all three proteins function as anti-oxidizing
enzymes that catalyze the dismutation of superoxide radicals
(O2•−) to hydrogen peroxide (H2O2), they are distinct proteins
with unique characteristics (Zelko et al., 2002). SOD1 is highly
abundant, comprising ∼1% of total protein in the cell (Pardo
et al., 1995), and resides mainly in the cytosol with some degree of
localization in the mitochondrial inner membrane space (Fukai
and Ushio-Fukai, 2011). The mitochondrion is also home to
SOD2, which is localized to the mitochondrial matrix. In contrast
to both SOD1 and SOD2, SOD3 is predominately located outside
the cell in the extracellular matrix. Other key differences amongst
the SOD proteins include their quaternary structures and mech-
anism of superoxide dismutation: SOD1 is a homodimer while
SOD2 and SOD3 are homotetrameric proteins; SOD1 and SOD3
catalyze the dismutation of O2•− through the alternate reduction
and reoxidation of Cu2+, whereas SOD2 utilizes manganese (Mn)
as a redox active transition metal for this purpose. The role of
SOD in FALS, which will be discussed in detail below, is specific to
the SOD1 isoform as there is no compelling evidence supporting
the involvement of either SOD2 or SOD3 in FALS pathogenesis
(Tomkins et al., 2001).
While coordination of copper to SOD1 is required for dismu-
tation of O2•−, other post-translational modifications, such as
Zn2+ coordination (Kayatekin et al., 2008) and disulfide oxida-
tion, help create a mature and structurally stable protein. The
32 kDa homodimeric SOD1 protein adopts an eight-stranded
Greek key beta-barrel structural motif (Figure 1A). Two func-
tional loops are present in SOD1: the electrostatic loop that guides
superoxide into the redox active site where Cu2+ is located and
the zinc-binding loop. All tolled, each SOD1 molecule coordi-
nates two copper and two zinc atoms, one of each per subunit.
A unique functional feature of SOD1 is the presence of an intra-
subunit disulfide bond between Cys57 and Cys146 (C57–C146),
which is unusual for proteins that reside in the highly reduc-
ing environment of the cytosol. Both copper coordination and
formation of C57-C146 is facilitated by the cytosolic copper car-
rier protein CCS (copper chaperone for SOD1) (Furukawa et al.,
2004; Seetharaman et al., 2009). A recent study utilizing both
electrospray ionization mass spectrometry (ESI-MS) and nuclear
magnetic resonance (NMR) spectroscopy support a step-wise
model for SOD1 maturation: (i) SOD1 is loaded with Zn, (ii)
heterodimerization between SOD1 and CCS, (iii) Cu is trans-
ferred from CCS to SOD1, (iv) C57–C146 is formed, and (v)
SOD1 homodimerization (Banci et al., 2012). Together these
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FIGURE 1 | Structural features of SOD1. SOD1 is a homodimer with one
copper (orange) and one zinc (blue) per subunit (PDB:2C9V). (A) SOD1
consists of eight beta sheets that form the beta barrel core. The major
functional loops are the zinc binding loop (purple; residues 49–81) and
electrostatic loop (yellow; residues 124–139). An intramolecular disulfide
bond (C57–C146; green) stabilizes the protein structure. (B) Mapping the
ALS-linked mutations (red) onto the structure of SOD1 illustrates that these
mutations are present throughout the entire protein. (C) Alterations to
normal post-translational modifications, such as loss of the disulfide bridge
(C57–C146; green), demetallation and monomerization (not shown), as well
as aberrant modifications such as oxidation of amino acid side chains
(shown for Cys 111; red), cause WT SOD1 to misfold.
post-translational modifications produce a highly stable protein,
as evidenced by a high melting temperature (Tm) of ∼92◦C
and resistance to denaturation in both 6M GdmCl and 4%
SDS (Forman and Fridovich, 1973; Bartnikas and Gitlin, 2003).
Demetalation of SOD1 and/or reduction of C57–C146 destabi-
lizes the protein and drastically decreases the melting temperature
(Forman and Fridovich, 1973; Furukawa and O’Halloran, 2005).
As will be discussed below, these post-translational modifications
are compromised by both FALS-linked mutations and oxidation,
which in turn destabilize SOD1 in the context of disease.
SOD1 IN SIGNAL TRANSDUCTION
The physiological relevance of SOD1 catalysis extends beyond
oxidative stress protection. In fact, SOD1 catalysis plays a key
role in signal transduction, a function that is largely under-
appreciated compared to its role as an anti-oxidizing enzyme
(Figure 2). For instance, H2O2 generated by SOD1 can reversibly
and specifically react with proteins, generally by oxidizing Cys
residues. Cys oxidation in turn alters the biochemical and func-
tional properties of those proteins in a redox dependent manner
(Georgiou, 2002). A variety of signal transduction pathways are
modulated by H2O2, including but not limited to gene expres-
sion, cell proliferation, differentiation and death (Rhee, 2006;
Brown and Griendling, 2009). NADPH oxygenases (Nox) func-
tion as upstream regulators of these signal transduction pathways
through the production of O2•−, which is either converted to
H2O2 spontaneously or catalytically by SOD1. SOD1 comes
into close proximity with Nox2-derived O2•− at the surface of
endosomes in response to proinflammatory cytokines (Harraz
et al., 2008). A report by Harraz et al. (2008) demonstrated that
SOD1 not only acts downstream of Nox2 but can also mod-
ulate Nox function through an interaction with Rac1. SOD1
directly binds and stabilizes the active form of Rac1 in its GTP-
bound state, leading to Nox2 activation and O2•− production.
Interestingly, H2O2 generated by SOD1 serves as a negative
feedback of Nox2 activity: H2O2 induces the dissociation of
the SOD1/Rac1 complex, thereby inactivating Rac1 and Nox2
(Harraz et al., 2008). The mechanism for how H2O2 disrupts
the interaction between SOD1 and Rac1 has not been eluci-
dated. One possibility is that the H2O2 generated by SOD1, which
is in close proximity to Rac1, oxidatively modifies Cys residues
within Rac1 in such a way that disrupts the SOD1/Rac1 binding
interaction.
Another example of SOD1 redox-sensing and signaling activ-
ity is in the context of respiratory repression, which occurs
during aerobic fermentation in proliferating cells, including in
the context of some cancers. In Saccharomyces cerevisiae, a loss
of SOD1 activity impairs respiratory repression (Sehati et al.,
2011). SOD1 was shown to modulate respiratory repression
through binding and stabilizing Yck1p and Yck2p, two casein
kinase 1-gamma homologs in yeast that inhibit respiration (Reddi
and Culotta, 2013). The authors speculate that SOD1 stabi-
lizes Yck1p/Yck2p through the action of the reaction product
H2O2, where oxidative modification of lysine residues within
Yck1p/Yck2p by H2O2 prevents their ubiquitination and degra-
dation by the ubiquitin-proteasome system. Therefore, both the
Rac1/Nox2 and Yck1p/Yck2p interactions with SOD1 demon-
strate that the catalytic action of SOD1 can direct the modifica-
tion and activity of specific protein substrates. In this manner,
SOD1 catalyzes a “molecular redox switch” that ultimately con-
trols protein function and signaling, much like phosphorylation.
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FIGURE 2 | The putative normal function of the native WT SOD1 protein.
(1) SOD1 is responsible for converting the toxic superoxide anion (O2•−) into
oxygen (O2) and hydrogen peroxide (H2O2), the latter of which is involved in
the modulation of multiple pathways through oxidation of exposed thiols. (2)
SOD1 binds and stabilizes Rac1 in its active, GTP bound state, resulting in
Nox2 (Nox) activation and superoxide production. The hydrogen peroxide
by-product of the dismutase reaction of SOD1 and superoxide anion
promotes the disassociation of SOD1 from the Rac1 complex, resulting in
Nox inactivation. (3) Secreted SOD1 plays a role in extracellular signaling
processes. The presence of extracellular SOD1 leads to an increase in
intracellular calcium via a mechanism involving the phospholipase C/protein
kinase C pathway.
While the catalytic activity of SOD1 is required for these inter-
actions, it is not simply to remove O2•− from circulation, but
rather to modulate signaling pathways in a redox sensitive man-
ner. One can imagine that redox signaling needs to be regulated,
as an excess of either O2•−or H2O2 would have deleterious effects
on the cell. The levels of H2O2 in the cell are further controlled by
the antioxidant enzymes catalase, peroxiredoxins and glutathione
peroxidases (Fukai and Ushio-Fukai, 2011), which convert H2O2
into water and oxygen.
Extracellular SOD1 has also been shown to play a role in
signaling. Although SOD1 is predominately localized to the cyto-
plasm, multiple reports have demonstrated that SOD1 is secreted
(Mondola et al., 1996, 1998, 2003; Cimini et al., 2002; Turner
et al., 2005). The presence of extracellular SOD1 can in turn
increase intracellular calcium levels (Mondola et al., 2004), a
phenomena shown to have neuroprotective effects on cerebel-
lar granular neurons exposed to a dopaminergic toxin (Polazzi
et al., 2012). This increase in intracellular calcium results from
SOD1 activating the phospholipase C/protein kinase C pathway,
a pathway implicated in calcium homeostasis (Mondola et al.,
2004) through a mechanism involving signal transduction of
the muscarinic acetylcholine M1 receptor (M1) (Damiano et al.,
2013). Moreover, M1 activation in response to extracellular SOD1
jumpstarts downstream pathways such as the extracellular reg-
ulated protein kinase (ERK 1/2) and the Akt signaling cascades
(Damiano et al., 2013). Unlike the previous SOD1 signaling path-
ways discussed above, the activation of the M1 receptor does not
appear to be dependent upon the production of O2•−, as the
ROS scavenger N-acetylcysteine did not alter the signaling effect
of SOD1 in this context.
SOD1 MISFOLDING: LESSONS FROM FAMILIAL ALS
For the past 20 years, mutant-SOD1 has been the most intensely
studied molecule in the ALS field. Studies in animal and cell
culture models, as well as extensive biochemical and biophysical
analyses of recombinant mutant-SOD1 proteins have collectively
revealed a gain-of-toxic mechanism formutant-SOD1 in ALS that
is linked to its propensity to misfold. Aberrantly modified WT
SOD1 adapts a conformation and toxic nature much like FALS-
linked SOD1 mutants, and is therefore proposed as a pathogenic
factor in SALS. Below we introduce what is known about the
structure and aberrant properties of FALS-SOD1.
FALS-LINKED SOD1 MUTATIONS: EFFECT ON STRUCTURE AND
CONFORMATION
Currently, 171 mutations have been identified within SOD1 that
are linked to ALS (http://alsod.iop.kcl.ac.uk/) (Abel et al., 2012).
Approximately 20–25% of FALS cases and 6% of all ALS cases
are caused by mutations in SOD1 (Pasinelli and Brown, 2006).
The majority of these mutations (>80%) result in amino acid
substitutions while the remaining lesions are a combination of
insertions, polymorphisms, and deletions. FALS-linked muta-
tions are not localized to one portion of SOD1, but rather span
the entire protein (Figure 1B). Moreover, relatively conservative
amino acid substitutions within SOD1 can cause ALS, suggest-
ing that even minor alterations severely affect SOD1 structure
and/or function. Much effort has been focused on determining
the common “toxic” feature within SOD1 that is induced by all
of these ALS-linked mutations. Except for the mutations that
directly interfere with metal coordination, as copper coordina-
tion is required for catalytic activity, many ALS-linked mutations
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have no effect on SOD1 dismutase activity (Borchelt et al., 1994;
Bowling et al., 1995; Hayward et al., 2002; Potter and Valentine,
2003). The effect of ALS-linked mutations on SOD1 signaling
activity remains largely unexplored. However, in the context of
Nox2 signaling, FALS-linked SOD1 mutations were shown to
alter the SOD1/Rac1 interaction, resulting in persistent activation
of Nox2 and abnormally high levels of ROS (Harraz et al., 2008).
A general feature of FALS-linked SOD1 mutants is that
they are destabilized and exhibit reductions in Tm relative to
WT SOD1 (Stathopulos et al., 2006; Vassall et al., 2006). In
fact, FALS-linked SOD1 mutants are further destabilized when
normal post-translational modifications such as Cu/Zn coordi-
nation and C57–C146 oxidation are impaired (Furukawa and
O’Halloran, 2005; Rodriguez et al., 2005; Kayatekin et al., 2010;
Svensson et al., 2010), demonstrating interconnection between
normal post-translational modifications and the stability of
SOD1. Additionally, mutant SOD1 exhibits an altered tertiary
structure, evidenced by enhanced hydrophobicity compared to
WT SOD1 (Tiwari et al., 2005; Munch and Bertolotti, 2010).
While X-ray crystallography has failed to reveal significant struc-
tural differences between WT- and mutant-SOD1 proteins, (Hart
et al., 1998; Elam et al., 2003; Hough et al., 2004; Cao et al.,
2008; Galaleldeen et al., 2009), solution-based structural stud-
ies indicate that FALS-linked mutations induce some degree of
SOD1 unfolding, or “misfolding” (Figure 3), within the electro-
static and/or zinc loops (Figure 1). For example, NMR relaxation
experiments reveal an overall increase in protein dynamics for
SOD1 G93A compared to WT SOD1 (Shipp et al., 2003). The
region proximal to the G93A mutation, termed the “β-barrel
plug,” as well as residues within the zinc-binding loop exhibited
the greatest increase in mobility, whereas the dynamics within
the electrostatic loop were comparable between SOD1 G93A and
WT (Shipp et al., 2003). Similarly, β-strands 3 and 4, which
contain the β-barrel plug, displayed high deuterium exchange
rates as assessed by mass spectrometry for several demetallated
mutant forms of SOD1 (Durazo et al., 2009). In a separate study
using similar methodology but with metallated forms of SOD1,
only 1 out of the 13 mutants exhibited relatively high deuterium
exchange rates in the β-barrel plug (Molnar et al., 2009). However,
this study detected a 10–31% increase in deuterium exchange
within the electrostatic loop for 7 out of 8 “WT-like” ALS-linked
SOD1 mutants (i.e., mutant-SOD1 proteins that coordinate Cu
and Zn), including A4V. Deuterium exchange increased within
both the electrostatic and zinc binding loops for those SOD1
mutants with impaired metal binding (Molnar et al., 2009).
The generation of conformation specific antibodies has also
provided important insights into the misfolded nature of FALS-
linked mutant-SOD1 proteins. Most conformation specific anti-
bodies reported to date are selectively reactive for mutant SOD1
over WT SOD1, consistent with the notion that mutations induce
some degree of misfolding that exposes linear sequences or con-
formational epitopes that are otherwise buried in the intact,
native protein (Rakhit et al., 2007; Urushitani et al., 2007; Liu
et al., 2009; Bosco et al., 2010; Forsberg et al., 2010; Gros-
Louis et al., 2010; Grad et al., 2011; Brotherton et al., 2012;
Fujisawa et al., 2012; Broering et al., 2013) (Figure 4, Table 1).
For example, the conformation specific antibodies B8H10, D3H5,
and A5C3 that were generated against apo-SOD1 G93A do
not immunoprecipitate WT SOD1, but rather exhibit differen-
tial reactivity for various mutant-SOD1 proteins (G93A, G37R,
G85R, G127X, and D90A) from spinal cord lysates derived from
the respective ALS mouse models. That B8H10, D3H5, and A5C3
FIGURE 3 | Misfolded vs. aggregated SOD1. Misfolded SOD1 results from
both ALS-linked mutations and aberrant post-translational modifications.
Throughout the review, the term “misfolding” refers to the structural
loosening of SOD1 due to a mutation and/or altered post-translational
modification within a soluble form of the protein. Misfolded, soluble SOD1
can engage in aberrant protein-interactions and acquire new toxic functions
(illustrated in Figure 5). Misfolded SOD1 can also assemble into aggregates.
In this review, “aggregates” refer to those insoluble species characteristic of
end-stage pathological inclusions present in human post-mortem CNS
tissues.
FIGURE 4 | Conformation specific antibodies highlight regions
exposed in SOD1 upon misfolding. The primary sequence for
WT SOD1 is shown with the secondary structure displayed
below. The binding regions of 11 antibodies specific for
misfolded SOD1 are depicted above the sequence (see Table 1
for antibody details).
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Table 1 | Conformation specific antibodies recognize regions of SOD1 exposed upon misfolding.
Antibody SOD1 epitope (aa) Reactive for
FALS SOD1
Reactive for SALS SOD1 Therapeutic
benefits
Reference
Patient tissue Modified SOD1
B8H10e 57–78a + ndb nd nd Gros-Louis et al., 2010; Pickles et al., 2013
C4F6e 80–118 + + + (ox) nd Urushitani et al., 2006; Bosco et al., 2010;
Prudencio and Borchelt, 2011; Brotherton
et al., 2012; Pickles et al., 2013
MS785 6–16 + nd +c nd Fujisawa et al., 2012
D3H5 24–55a + nd + (apo) + Gros-Louis et al., 2010
A5C3e 80–118a + nd nd − Gros-Louis et al., 2010
SEDI 143–151 + − + (ox) +d Rakhit et al., 2007; Liu et al., 2009, 2012;
Kerman et al., 2010; Prudencio and
Borchelt, 2011; Mulligan et al., 2012
USOD 42–48 + − − (ox) nd Kerman et al., 2010; Mulligan et al., 2012
DSE2 (3H1) 125–142 + + nd nd Vande Velde et al., 2008; Grad et al., 2011;
Pokrishevsky et al., 2012
4–20Ra-ab 4–20 + + nd nd Jonsson et al., 2004; Forsberg et al., 2010
57–72Ra-ab 57–72 + + nd nd Stewart et al., 2006; Forsberg et al., 2010,
2011
131–153Ra-ab 131–153 + + nd nd Jonsson et al., 2004; Forsberg et al., 2010,
2011
Misfolded SOD1-specific antibodies highlight regions in SOD1 that become exposed as a result of misfolding.
aDetermined using similar methodology as in C4F6 epitope mapping (Bosco et al., 2010) (unpublished data, Bosco DA).
bnd, Not determined.
cSerum starvation in cultured cells results in SOD1 reactivity with antibody.
d Benefits observed from active immunization with SOD1 peptide recognized by SEDI.
eCommercially Available.
become reactive for denatured WT SOD1 is consistent with a
linear epitope within natively folded WT SOD1 that is exposed
only upon SOD1 unfolding (Gros-Louis et al., 2010). The C4F6
antibody is also selective for FALS-linked SOD1 mutants G37R,
G85R, G93A (Urushitani et al., 2007) A4V (Brotherton et al.,
2012) over WT SOD1 when these proteins are in their native state
but exhibits weak reactivity for denatured SOD1 proteins, sug-
gesting that this antibody recognizes a conformational epitope
(Bosco et al., 2010). Interestingly, both D3H5 (Gros-Louis et al.,
2010) and C4F6 (Brotherton et al., 2012) immunoreactivity for
SOD1 G93A directly correlates with disease progression in the
transgenic SOD1 G93A ALS mouse model, indicating that these
antibodies report on the presence of “toxic,” misfolded forms of
SOD1 G93A.
In contrast to the aforementioned antibodies, for which the
epitope within SOD1 remains unknown, several conformation
specific antibodies have been generated against sequences that
are predicted to become exposed only upon SOD1 misfolding
(Rakhit et al., 2007; Grad et al., 2011; Fujisawa et al., 2012).
One such antibody, MS785, targets amino acids 6-16 at the
N-terminus of SOD1. This portion of mutant SOD1 is impli-
cated in binding Derlin-1, a protein involved with ER associated
degradation, and is thus referred to as the Derlin-1 binding region
(DBR). Fujisawa et al., demonstrated through immunoprecipi-
tation experiments that mutant-SOD1 associates with Derlin-1
when coexpressed in HEK cells. Their comprehensive immuno-
precipitation strategy assessed the interaction between Derlin-1
and 132 ALS-linked SOD1 mutants, of which 124 were found to
associate with Derlin-1. Further, MS785 selectively immunopre-
cipitated SOD1 from B-lymphocytes derived from all 14 SOD1
positive ALS cases examined but not from 11 healthy controls
(Fujisawa et al., 2012). An alternative antibody called SEDI was
created against an epitope at the opposite end of the SOD1
molecule. SEDI stands for SOD1 Exposed Dimer Interface and
was raised against the amino acids 143–151 located at the dimer
interface in SOD1 (Rakhit et al., 2007). SEDI reactivity is spe-
cific for mutant SOD1 over native WT SOD1 in the context of
transgenic mouse tissue [G37R, G93A, and G85R (Rakhit et al.,
2007)] and human post-mortem tissues harboring SOD1 muta-
tions [A4V (Rakhit et al., 2007), A4T, V14M, G27/P28, and
I113T (Liu et al., 2009)]. Therefore, MS785 and SEDI antibod-
ies report on misfolding events within the N- and C-termini,
respectively, that are induced by ALS-linked mutations.
A direct consequence of mutation-induced misfolding of
SOD1 is aggregation, which refers to the irreversible assembly of
misfolded SOD1 species into an insoluble structure (Figure 3).
SOD1 aggregation has been extensively investigated in vivo, both
in ALS human post-mortem tissues and in mutant-SOD1 trans-
genic mice. The enhanced aggregation propensities of FALS-
linked SOD1 mutants have also been comprehensively examined
in cell culture and in other in vitro assays. We refer the reader
to many excellent reviews and original works that detail cur-
rent models of mutant-SOD1 aggregation (Durham et al., 1997;
Bruijn et al., 1998; Johnston et al., 2000; Stathopulos et al., 2003;
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Furukawa et al., 2006; Wang et al., 2008; Prudencio et al., 2009)
Review: (Chattopadhyay and Valentine, 2009; Turner and Talbot,
2008).
Although it remains unclear whether SOD1 aggregation is
a causative or protective factor in disease progression, several
recent reports demonstrate that misfolded SOD1 species can
spread from cell to cell in a prion-like fashion (Grad et al.,
2011; Munch et al., 2011; Sundaramoorthy et al., 2013). Munch
et al demonstrated that the uptake of aggregated ALS-linked
SOD1 mutants in cultured neuronal cells seeded aggregation
of endogenous mutant-SOD1. These endogenous SOD1 aggre-
gates persisted well after (>30 days) the original aggregates
dissipated from cell division, consistent with a prion-like propa-
gation of aggregated SOD1 (Munch et al., 2011). More recently,
uptake of both misfolded mutant-SOD1 as well as aggregated
mutant-SOD1 was shown to induce aggregation of the native WT
SOD1 protein (Sundaramoorthy et al., 2013). This latter report
demonstrates howmisfolded SOD1 can alter the conformation of
otherwise normally folded SOD1, however, it remains to be deter-
mined whether this spreading of misfolded and aggregated SOD1
directly impacts ALS pathogenesis in vivo (Guest et al., 2011).
MISFOLDED FALS-LINKED SOD1 EXERTS A GAIN OF TOXIC FUNCTION
IN ALS
Studies using transgenic rodent models have generated themajor-
ity of data pointing to a gain of toxic mechanism for mutant-
SOD1 in FALS (Turner and Talbot, 2008). Several transgenic
mouse models have been engineered to overexpress ALS-linked
SOD1 mutants. Mutant-SOD1 transgenic mice develop an ALS-
like phenotype that includes motor neuron degeneration, neu-
roinflammation, severe paralysis and premature death (Gurney
et al., 1994; Dal Canto and Gurney, 1995; Wong et al., 1995;
Bruijn et al., 1997; Dal Canto and Gurney, 1997). In addition,
cytosolic SOD1-containing ubiquitinated aggregates are detected
within CNS tissues from these mice, recapitulating the patho-
logical features of the human disease (Gurney et al., 1994; Dal
Canto and Gurney, 1995; Bruijn et al., 1997; Dal Canto and
Gurney, 1997;Watanabe et al., 2001). These mice express endoge-
nous murine SOD1, and yet develop motor neuron disease upon
expression of exogenous human mutant-SOD1, providing evi-
dence that SOD1 mutations lead to a gain of toxic function.
Further, SOD1-deficient mice develop normally with no overt
signs of neurodegeneration (Reaume et al., 1996). However, it
is noted that SOD1 null mice are more susceptible to axonal
(Reaume et al., 1996) and ischemic brain (Kondo et al., 1997)
injuries, and therefore a complete loss of SOD1 may be disadvan-
tageous, especially in the context of disease (van Blitterswijk et al.,
2011).
Because the aforementioned SOD1 pathological aggregates are
a downstream consequence of SOD1 misfolding, the presence of
such aggregates in human post-mortem tissues and ALS-mice
argues for a role of misfolded SOD1 in disease. This notion
is supported by immunization strategies that both target mis-
folded SOD1 species and have therapeutic outcome in ALS mice.
A passive immunization strategy with the D3H5 antibody that
specifically reacts with misfolded SOD1 extended survival in
SOD1 G93A transgenic mice (Gros-Louis et al., 2010)(Figure 4,
Table 1). A greater therapeutic impact was shown in active immu-
nization trials with the SOD1 G37R transgenic mouse model,
using both recombinant apo-SOD1 G93A (Urushitani et al.,
2007) and the SEDI (SOD1 exposed dimer interface) peptide
(Liu et al., 2012) as immunogens. Use of SEDI increased survival
and delayed disease onset to a greater extent than the full-length
SOD1 immunogen, likely due to specific targeting of a misfolded
toxic epitope within mutant-SOD1 (Liu et al., 2009, 2012). While
these studies provide a direct correlation between misfolded
SOD1 species and disease in mice, a survival benefit was not
realized using humanized SOD1 antibodies in SOD1 transgenic
mice (Broering et al., 2013). Going forward, immunotherapeutic
strategies in humans may require the specific targeting of regions
within SOD1 that are only exposed upon misfolding. Moreover,
these regions should mediate some toxic effect in vivo, so that
antibodies have the potential to neutralize or otherwise block
that “toxic epitope.” The latter criterion is important in light of
the fact that not all mutant-specific antibodies have produced a
therapeutic outcome in SOD1 transgenic mice (Gros-Louis et al.,
2010).
The immunization studies described above demonstrate that
misfolded SOD1 can impact the disease course in ALS mice.
What evidence supports a toxic role of misfolded and/or aggre-
gated SOD1 in the human disease? Wang et al., found an inverse
correlation between SOD1 aggregation propensity and disease
duration in human ALS cases (i.e., mutants that are more aggre-
gation prone are associated with cases that exhibit relatively
short survival) using the Chiti-Dobson equation (Wang et al.,
2008). A complementary study determined the relative aggre-
gation propensities of 30 SOD1 mutants in a cell culture assay
and also reported an indirect correlation between SOD1 aggre-
gation propensity and disease duration (Prudencio et al., 2009).
However, this correlation was not statistically significant, pos-
sibly due to the limited number of SOD1 mutants that could
be included in this type of analysis that utilizes patient data
(Prudencio et al., 2009). Nonetheless, these studies implicate
misfolded SOD1 as a factor in human ALS pathogenesis.
TOXIC, SOLUBLE MISFOLDED FALS-SOD1 SPECIES IN DISEASE
While end-stage pathological aggregates composed of insolu-
ble mutant-SOD1 are detected in ALS-mouse models and in
the human disease, emerging evidence suggests that the toxic
SOD1 species is in fact a misfolded, soluble form of the pro-
tein (Figure 3). One can imagine that an aggregated, insoluble
form of SOD1, much like what is found at end stage of disease, is
isolated and unable to diffuse within the cell. Conversely, a non-
aggregated misfolded form of SOD1 is soluble, accessible, and
able to engage in aberrant interactions, thereby enabling a gain
of toxic function. To enumerate all of the aberrant functions and
interactions that have been observed for mutant-SOD1 is beyond
the scope of this review and therefore we refer the reader to
excellent reviews that cover this topic (Cleveland and Rothstein,
2001; Bruijn et al., 2004; Pasinelli and Brown, 2006; Joyce et al.,
2011). Herein, we will focus on those gain-of-toxic functions for
FALS-linked mutants that are thought to involve misfolded, sol-
uble SOD1 and that may also have relevance to sporadic ALS
(Figure 5).
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FIGURE 5 | The toxic properties shared by ALS-linked mutant SOD1
and modified WT SOD1. As shown, misfolded SOD1, resulting from
mutations or aberrant post-translational modifications, causes the protein
to engage in aberrant interactions. (1) Misfolded SOD1 is both
secreted, possibly through chromogranins, and taken up from the
extracellular environment. (2) Extracellular misfolded SOD1 activates
microglia by binding to the CD14/TLR4 receptor, thereby elevating nitric
oxide synthase (iNOS) activity as well as secretion of superoxide anion
(O2•−) and proinflammatory cytokines (e.g., TNFα). (3) Expression and
uptake of misfolded SOD1 leads to ER stress, which elevates the
pro-apoptotic CHOP protein and induces mitochondrial damage. (4) The
presence of misfolded SOD1 in the axon results in axonal transport
inhibition through a mechanism involving the phosphorylation of p38
MAPK and the kinesin motor. All of these aberrant functions
compromise the integrity of the motor neuron, and potentially
contribute to both FALS and SALS pathogenesis.
Support for a soluble misfolded form of SOD1 comes from
studies in both SOD1 animal models and cell culture. Zetterstrom
et al., identified an accumulation of soluble misfolded SOD1
that was enriched in the spinal cord of SOD1 G93A transgenic
mice. The fraction of solublemisfolded SOD1was quantified with
hydrophobic interaction chromatography (HIC) (Zetterstrom
et al., 2007). Interestingly, not only is the solubility of FALS-
linked SOD1 variants enhanced upon heterodimerization with
WT SOD1, but the toxicity of these variants is also enhanced,
consistent with the toxic SOD1 species being soluble-misfolded
rather than insoluble-aggregated (Witan et al., 2008, 2009). In
CHO cells, the fraction of soluble SOD1 was found to corre-
late with cellular toxicity (Brotherton et al., 2013). This cellular
toxicity was attenuated upon expression of exogenous hsp70
(Brotherton et al., 2013), a chaperone that refolds misfolded pro-
teins, although it is not clear whether this is due solely to a
reduced load of misfolded SOD1 or whether the anti-apoptotic
function of hsp70 also contributed to this effect (Beckmann et al.,
1990; Beere et al., 2000; Luders et al., 2000).
Misfolded mutant SOD1 can have downstream effects both
outside and inside the cell. Although WT SOD1 is known to
be secreted normally (Mondola et al., 1996, 1998, 2003; Cimini
et al., 2002; Turner et al., 2005; Urushitani et al., 2006; Santillo
et al., 2007), Urushitani et al. demonstrated that mutant-SOD1
can be secreted by an alternate pathway that involves the secre-
tory chromogranin proteins (Urushitani et al., 2006). In contrast,
Turner et al., demonstrated an impaired secretion of mutant
SOD1 compared to WT SOD1 (Turner et al., 2005). The dis-
crepancy between these studies may de due to the different cell
types employed. Nonetheless, both studies are consistent with a
dysregulation of mutant-SOD1 secretion compared to native WT
SOD1. Once secreted into the extracellular space, mutant-SOD1
activates microglia though a mechanism that involves binding to
the CD14/TLR receptor (Zhao et al., 2010), resulting in a typi-
cal proinflammatory response (i.e., increased levels of TNFα and
IL-1β). This mode of microglia activation leads to motor neuron
death (Urushitani et al., 2006; Zhao et al., 2010).
Inside the cell, mutant SOD1 can induce stress in the context
of various pathways. For example, primary neurons derived from
SOD1 G93A transgenic mice, as well as cell culture models of
mutant-SOD1, exhibit signs of ER stress including spliced XBP1
and induction of CHOP (Nishitoh et al., 2008; Prell et al., 2012).
ER stress has been shown to be a major player in ALS pathogen-
esis [reviewed in Kanekura et al. (2009), Matus et al. (2011)]. It
should be noted that endogenous expression of mutant-SOD1
is not required for activation of the ER stress response path-
way. Uptake of extracellular SOD1 G93A is sufficient to induce
ER stress and neuronal toxicity (Sundaramoorthy et al., 2013).
Thus, the combination of mutant-SOD1 uptake and intracellu-
lar expression in neurons could exacerbate ER stress, and tilt
the scale from the UPR coping mechanism toward apoptosis
in vivo. Mitochondria represent an additional intracellular com-
partment that is affected by mutant-SOD1 (Pickles et al., 2013).
Recent evidence indicates that mutant-SOD1 directly interacts
with Bcl-2, leading to exposure of the toxic BH3 domain, which
in turn causes mitochondrial damage (Pasinelli et al., 2004;
Pedrini et al., 2010). Interestingly, enhanced exposure of the BH3
domain has been detected in FALS SOD1 A4V patient spinal
cord homogenates, and increases as a function of disease in
spinal cords of SOD1 G93A transgenic mice (Pedrini et al., 2010).
Finally, much evidence suggests that mutant-SOD1 impairs the
process of axonal transport in different model systems (Morfini
et al., 2009). In studies of fast axonal transport (FAT) performed
in squid axoplasm, there is compelling evidence that it is a soluble
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misfolded form of mutant-SOD1 that inhibits transport in the
anterograde direction (Morfini et al., 2009, 2013; Song et al.,
2013). Moreover, these studies were extended to explore the
role of WT SOD1 in SALS, which is the topic of the following
section.
MISFOLDED WILD-TYPE SOD1: IMPLICATIONS FOR SALS
Since the discovery of FALS-linked mutations in SOD1 (Rosen
et al., 1993), there has been speculation that the wild-type ver-
sion of the protein could play a role in sporadic ALS (Selverstone
Valentine et al., 2005; Kabashi et al., 2007). It has become
increasingly clear that alterations of the normal post-translational
modifications of SOD1 and/or introduction of aberrant modifi-
cations in WT SOD1 cause this otherwise stable protein to mis-
fold and adapt properties similar to FALS-linked SOD1 mutants
(Figure 1C). Until recently, however, there was a lack of direct evi-
dence for aberrant forms of WT SOD1 in SALS. This is probably
because the field lacked the appropriate tools and methodologies
to detect such species. Below we describe modifications of WT
SOD1 that cause this protein to become misfolded and “toxic.”
We also present evidence, largely from the use of conformation
specific antibodies that recognize misfolded SOD1 species, that
support or contradict the hypothesis that WT SOD1 plays a role
in sporadic ALS.
LOSS OF NATIVE SOD1 POST-TRANSLATIONAL MODIFICATIONS LEADS
TO WT SOD1 MISFOLDING
As discussed above, coordination of Zn, oxidation of the
C57–C146 intrasubunit disulfide bond and homodimerization of
SOD1 contribute to the structural stability of the molecule. A loss
in integrity of any one of these normal post-translational modi-
fications compromises the stability of WT SOD1 and contributes
to its misfolding and aggregation (Figures 1C, 3). For example, a
reduction of WT SOD1 stability upon demetallation is a widely
documented observation (Stathopulos et al., 2003; Lynch et al.,
2004; Furukawa and O’Halloran, 2005; Ding and Dokholyan,
2008). Interestingly, demetallation of WT SOD1 induces simi-
lar conformational perturbations within the zinc binding and
the electrostatic loops (loops IV and VII, respectively, Figure 1)
as do FALS-linked SOD1 mutations (Strange et al., 2003, 2007;
Ding and Dokholyan, 2008; Durazo et al., 2009; Molnar et al.,
2009). A direct comparison of NMR backbone chemical shifts for
apo dimeric WT SOD1 vs. holo dimeric WT SOD1 revealed the
largest structural variations within the electrostatic loop (Banci
et al., 2009). These structural alterations were accompanied by
pronounced changes in backbone dynamics that further support
demetallation-induced misfolding (Banci et al., 2009). Molecular
dynamics (Ding and Dokholyan, 2008) and H/D exchange by
mass spectrometry (Durazo et al., 2009) also report enhanced
flexibility within the aforementioned loops of apo WT SOD1
compared to holo SOD1, but in addition these studies also detect
misfolding within the beta barrel of SOD1 upon demetallation
(Ding and Dokholyan, 2008; Durazo et al., 2009). Furthermore,
the misfolding of WT SOD1 induced by demetallation leads to
aggregation of the protein (Banci et al., 2007), which may be
driven by the exposure of hydrophobic regions within misfolded
SOD1 that are otherwise buried in the native protein (Tiwari
et al., 2009).
In addition to demetallation, reduction of the C57–C146 disul-
fide bond also has a destabilizing effect on WT SOD1 that can
lead to protein misfolding and aggregation in a manner simi-
lar to FALS-linked mutant SOD1 (Figure 3) (Furukawa et al.,
2008; Chan et al., 2013). Several studies have demonstrated that a
reduction of C57–C146 in apo-SOD1 shifts the monomer-dimer
equilibrium toward the monomeric state. Addition of zinc or oxi-
dation of C57–C146 shifts the equilibrium back to the dimeric
state, demonstrating interdependence between Zn coordination,
C57–C146 bond integrity, and dimerization on the structural
stability of SOD1 (Arnesano et al., 2004; Lindberg et al., 2004;
Hornberg et al., 2007).
INTRODUCTION OF ABERRANT POST-TRANSLATIONAL
MODIFICATIONS INDUCE WT SOD1 MISFOLDING
In addition to alterations of the normal post-translational modi-
fications of SOD1, WT SOD1 misfolding and aggregation can be
induced by the formation of aberrant modifications. Oxidation of
SOD1 side chains represents one such modification that has been
postulated to play a significant causal role in both FALS and SALS
(Kabashi et al., 2007). In the context ofWT SOD1, which has rele-
vance to SALS, metal catalyzed oxidation with CuCl2 and ascorbic
acid leads to oxidative modification of SOD1 histidine residues
and subsequent SOD1 aggregation (Rakhit et al., 2002, 2004).
This mode of oxidation-induced SOD1 aggregation proceeds by
way of SOD1 dimer dissociation/monomer formation, demon-
strating interdependence between aberrant and normal SOD1
post-translational modifications (Rakhit et al., 2004). Cys111
within SOD1 is particularly susceptible to H2O2 induced oxida-
tion (Figure 1C). Prolonged exposure of SOD1 to H2O2 results
in the irreversible conversion of the Cys111 sulfhydryl group to
sulfonic acid (Fujiwara et al., 2007; Bosco et al., 2010; Auclair
et al., 2013), which may be detrimental since WT SOD1 oxidized
by H2O2 (hereafter referred to as SOD1ox) exhibits an enhanced
propensity to misfold and aggregate (Ezzi et al., 2007; Fujiwara
et al., 2007; Bosco et al., 2010; Chen et al., 2012). Interestingly,
modifications such as β-mercaptoethanol (Fujiwara et al., 2007),
persulfide (de Beus et al., 2004) and cysteinylation (Auclair et al.,
2013) on Cys111 protect SOD1 against oxidation and possibly
against subsequent misfolding.
ABERRANTLY MODIFIED WT SOD1 PROTEINS ARE TOXIC AND MIMIC
FALS-LINKED SOD1 MUTANTS
The observation that zinc depleted WT SOD1 exerts a toxic effect
onto motor neurons by a mechanism involving nitric oxide pro-
vided one of the first clues that modified WT SOD1 species are
toxic and may contribute to SALS pathogenesis (Estevez et al.,
1999; Beckman et al., 2001). More recently, zinc-deficient SOD1
was shown to exhibit a toxic effect related to mitochondrial dys-
function in Drosophila (Bahadorani et al., 2013). That metal
deficient WT SOD1 can be induced to misfold and exhibit a
toxic nature analogous to FALS-linked SOD1 is supported by the
immunization trial in ALS mice reported by Takeuchi et al. Low
copy SOD1 G93A transgenic mice vaccinated with the apo WT
SOD1 immunogen exhibited delayed disease onset and prolonged
survival compared to control mice injected with saline/adjuvant,
and importantly, to a similar degree as mice vaccinated with apo
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SOD1 G93A (Takeuchi et al., 2010). This study also implicates
WT SOD1 as a viable therapeutic target for SALS.
In recent years, several reports have demonstrated a toxic
effect of SOD1ox in the context of ALS relevant pathways
and processes (Figure 5). For example, SOD1ox acquires aber-
rant protein-interactions that are also observed for FALS-linked
SOD1 mutants. SOD1ox interacts with the heat shock protein
Hsc70 that plays a role in refolding misfolded proteins (Ezzi
et al., 2007), the secretory protein chromagranin B that actively
secretes misfolded forms of SOD1 (Urushitani et al., 2006; Ezzi
et al., 2007), and the anti-apoptotic protein Bcl-2 in a man-
ner that induces mitochondrial damage (Pasinelli et al., 2004;
Guareschi et al., 2012). SOD1ox was also shown to mimic FALS-
linked SOD1 mutants in the inhibition of anterograde FAT in
squid axoplasm. These studies demonstrated that the inhibitory
effect of SOD1ox and mutant SOD1 was mediated by acti-
vated p38 MAPK, indicating that misfolded SOD1 can trigger
kinase-dependent signaling cascades (Morfini et al., 2009; Bosco
et al., 2010; Morfini et al., 2013; Song et al., 2013). Extracellular
derived WT SOD1 can also induce a toxic effect onto cells.
SOD1ox applied to cell culture media activates immortalized
microglia (Ezzi et al., 2007), which in turn may cause motor
neuron death (Ezzi et al., 2007; Zhao et al., 2010). Furthermore,
uptake of aggregated WT SOD1 species by macropinocytosis
in neuronal cells caused ER stress and seeded the aggrega-
tion of intracellular, endogenous SOD1 (Sundaramoorthy et al.,
2013).
Studies in various SOD1 transgenic ALS mouse models have
provided direct evidence for WT SOD1 mediated toxicity in vivo.
Intriguingly, an ALS-like phenotype was only observed in trans-
genic mice expressing the human SOD1 A4V variant, a mutation
that corresponds to an aggressive ALS phenotype in humans,
when these mice expressed the human WT version of SOD1
(Deng et al., 2006). This paradoxical result may be explained by
heterodimerization of WT and A4V subunits, affording a “sta-
bilized” and thus more toxic version of SOD1 A4V that would
otherwise be degraded (Witan et al., 2008, 2009). A similar phe-
nomenon was observed in double-transgenic mice expressing
human SOD1 WT and G85R, where disease onset was has-
tened relative to single-transgenic SOD1 G85R mice (Wang et al.,
2009). Recently, a transgenic mouse model was developed that
over-expresses human WT SOD1 at similar levels to the estab-
lished high-copy SOD1 G93A mouse model (Gurney et al., 1994;
Graffmo et al., 2013). Compared to transgenic mice expressing
fewer copies of the human WT SOD1 gene, the mice generated
by Graffmo et al exhibit an ALS-like phenotype that includes
significant weight loss, SOD1 aggregation, neurodegeneration,
gliosis, and a shortened life-span of ∼360 days (Graffmo et al.,
2013). The authors posit that the ALS-like phenotype is not
a general effect of SOD1 overexpression per se, but rather a
direct consequence of a substoichiometric population of mis-
folded SOD1. Although the exact mechanism for WT SOD1
mediated toxicity is not well understood in these models, and
the extent to which WT SOD1 is post-translationally modified
has not been addressed, these studies clearly demonstrate a link
between WT SOD1 and motor neuron degeneration characteris-
tic of ALS.
EVIDENCE FOR MISFOLDED, TOXIC WT SOD1 SPECIES IN SALS
There is accumulating evidence that WT SOD1 can misfold
in vitro and exert a toxic effect in vivo. That genetic mutations
in SOD1 are sufficient to cause ALS raises the possibility that
modified forms of WT SOD1 may cause SALS, especially because
modified WT SOD1 closely mimics the toxic behavior of FALS-
linked SOD1mutants in the context of numerous assays described
above. To date, there is no animal model for SALS. Therefore,
investigations into the relevance ofWT SOD1 in SALS are focused
on biological samples from individuals with this disease.
Early immunohistochemistry (IHC) studies using pan-SOD1
antibodies detected SOD1 within Lewy body-like inclusions in
spinal cord sections from individuals with SALS (Shibata et al.,
1994, 1996), implicating WT SOD1 in SALS pathology. However,
pan-SOD1 antibodies failed to detect SOD1 containing aggre-
gates in every IHC study that included SALS cases (Watanabe
et al., 2001). In recent years, conformation specific antibodies
have been developed that discriminate between native WT SOD1
and mutant and/or misfolded SOD1. These antibodies are being
employed using IHC to address whether misfolded WT SOD1 is
in fact present in post-mortem SALS tissues [Figure 4, Table 1,
reviewed in Bosco et al. (2011), Furukawa (2012)]. Forsberg et
al generated multiple polyclonal antibodies against small peptide
sequences spanning the entire SOD1 protein. Two antibodies tar-
geted to amino acids 4–20 within β-strands 1 and 2, and amino
acids 131–153 that includes both the electrostatic loop and the
SOD1 dimer interface [i.e., the same sequence used to develop
the SEDI antibody Rakhit et al. (2007)] were shown to detect
SOD1-containing aggregates within the motor neurons of all 29
sporadic cases examined and punctate staining in only 2 out of 19
non-neurological controls (Forsberg et al., 2010). The C4F6 con-
formation specific antibody introduced earlier was shown to react
with misfolded WT SOD1 in a subset (4 out of 9) of SALS spinal
cord sections (Bosco et al., 2010), but produced a diffuse staining
pattern as opposed to a punctate pattern that would be consistent
with insoluble aggregates (Bosco et al., 2010; Brotherton et al.,
2012). The DSE2 antibody, which recognizes a “Disease-Specific
Epitope” located within the electrostatic loop that is only exposed
when SOD1 is misfolded (Vande Velde et al., 2008), was shown
to detect misfolded SOD1 within SALS cases that also exhibit
TDP-43 pathology (Pokrishevsky et al., 2012). Although these
conformation specific antibodies appear to recognize different
types ofWT SOD1 species (i.e., soluble misfolded vs. aggregated),
these reports collectively implicate SOD1 in SALS.
However, not all SOD1 conformation specific antibodies have
detectedmisfolded or aggregated SOD1 in SALS cases. The USOD
antibody, which was generated against residues 42–48 within
“Unfolded SOD1” failed to detect misfolded SOD1 in SALS cases
as did the SEDI antibody, whereas both antibodies detected aggre-
gated SOD1 in FALS (Liu et al., 2009; Kerman et al., 2010).
Furthermore, some antibody studies have produced conflicting
results. While Bosco et al did not detect C4F6 reactivity in 17 con-
trol spinal cord sections, Brotherton et al., reported C4F6 reactiv-
ity in SALS tissues as well as tissues from controls (Brotherton
et al., 2012). The source of these discrepancies is not clear, and
may stem from technical differences in the experimental proce-
dures, inherent variations in the nature of these antibodies (i.e.,
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different epitopes) or inconsistancies amongst the SALS cases
utilized across studies.
Biochemistry-based methods offer an alternative approach to
IHC for the investigation of misfolded WT SOD1 in SALS. One
study reported that SOD1 present in FALS and SALS spinal cord
extracts is more susceptible to forming a 32 kDa cross-linked
species upon treatment with a biotinylation reagent, suggestive
of a misfolded SOD1molecule that is common to FALS and SALS
(Gruzman et al., 2007). This 32 kDa species, however, was later
identified as carbonic anhydrase and not misfolded SOD1 (Liu
et al., 2010). Subsequently, SOD1 immunopurified from SALS
spinal cord tissues was shown to inhibit FAT in squid axoplasm
to the same extent as recombinant forms of both oxidized WT
and FALS-linked mutant SOD1 (Bosco et al., 2010). Although
misfolded SOD1 has been detected in SALS tissues with different
antibodies by IHC, this study demonstrated that SOD1 derived
from SALS tissues could in fact exert a “toxic” effect in an ALS-
relevant assay (Bosco et al., 2010; Yates, 2010). Importantly, this
effect was blocked by C4F6 (Bosco et al., 2010), indicating that
C4F6 reports on the toxic region within SOD1 and therefore may
be useful for designing immunotherapeutic strategies for humans
with ALS.
Haidet-Phillips et al. further demonstrated the toxic nature of
SOD1 in the context of SALS, as astrocytes derived from human
SALS spinal cords exert a toxic effect onto motor neurons only
when they expressed near-endogenous levels of SOD1 (Haidet-
Phillips et al., 2011). This is consistent with the observation of
misfolded SOD1 in glia (Forsberg et al., 2011). Moreover, an
ELISA designed for the detection of auto-SOD1 antibodies in
human sera demonstrated that these antibodies can influence
the SALS disease course. Elevated auto-SOD1 antibodies reac-
tive for the misfolded oxidized form of WT SOD1 conferred a
survival benefit within the SALS cohort examined, whereas those
cases with elevated auto-SOD1 antibodies against the native WT
SOD1 exhibited shorter survival (van Blitterswijk et al., 2011).
These data are consistent with a toxic effect of misfolded SOD1
in human SALS, but also indicate a disadvantage to lowering
endogenous levels of normal WT SOD1 in SALS. Therefore, it
may be necessary to avoid immunotherapeutic and anti-sense
oligonucleotide strategies that reduce levels of the normal, native
WT SOD1 protein.
The actual molecular nature of “toxic” WT SOD1 species
within the aforementioned human SALS studies was not
addressed, and therefore it is not clear whetherWT SOD1 in SALS
exhibits aberrant post-translational modifications. It is intrigu-
ing that the H2O2 product of the dismutation reaction that is
catalyzed by SOD1 (Figure 2) can also induce the conversion
of this otherwise normal protein into a misfolded, toxic species
(Ezzi et al., 2007; Bosco et al., 2010). A report by Guareschi
et al., may shed some light onto the nature of the SOD1 modi-
fications in vivo, as elevated levels of carbonylated SOD1 species
were detected in lymphoblast cell lines from a subset of SALS
patients with bulbar onset (Guareschi et al., 2012). An over-
oxidized form of WT SOD1 that could explain both SOD1
misfolding and toxicity in SALS is reasonable, considering that
oxidative stress is a pathological hallmark of SALS (D’Amico et al.,
2013).
While there is compelling data supporting that misfolded
and/or aggregated WT SOD1 is associated with SALS, it is still
unclear whether WT SOD1 can cause SALS. The existing data
cannot exclude the possibility that misfolded SOD1 is simply
a downstream effect of disease. In fact, oxidized SOD1 has
been detected in the brains of individuals with Alzheimer’s and
Parkinson’s disease (Choi et al., 2005). Moreover, the confor-
mation specific antibodies that detect misfolded and aggregated
SOD1 in SALS also detect misfolded SOD1 in SOD1-negative
FALS cases as well as in the context of other neurodegenerative
disorders (Forsberg et al., 2010, 2011; Brotherton et al., 2012;
Pokrishevsky et al., 2012). Therefore, misfolded SOD1 may rep-
resent a general consequence of aging and disease. Nonetheless,
one would still expect the presence of misfolded SOD1, whether
it be the mutant or WT form, to exacerbate disease based on
all of the data demonstrating the toxic effects associated with
these proteins. Several therapies are under development, with
some in clinical trials, that target SOD1 (Glicksman, 2011). It
will be important to determine whether any SOD1-based ther-
apies can confer a therapeutic benefit to those individuals with
SALS as well as FALS. Such an outcome would provide unequiv-
ocal evidence that SOD1 is indeed a pro-active factor is SALS
pathogenesis.
FUTURE OUTLOOK
There is an indisputable role for mutant-SOD1 in FALS; how-
ever, whether there is an analogous role for WT SOD1 in the
context of SALS is unclear and controversial. The evidence that
misfolded WT SOD1 is present in human post-mortem SALS
samples, together with two decades worth of evidence that mis-
folded SOD1 can exert a toxic effect onto cells, supports the
hypothesis thatWT SOD1 is a causal factor in SALS. However, the
presence of misfolded WT SOD1 may simply represent a down-
stream, non-specific consequence of aging and disease. Because
SALS accounts for 90% of ALS cases, and the field is lacking an
effective therapy for this devastating disease, a role for misfolded
WT SOD1 in the pathogenesis of SALS should be considered.
Such a role may include an upstream trigger of the disease, and/or
a factor that promotes disease progression. As therapies become
available to treat SOD1 in the context of FALS, it will be impor-
tant to assess whether these therapies can also be applied to all or
at least a subset of SALS.
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